Your Article Summary
See Latest ArticlesAntiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection
Expert Opinion in Pharmacotherapy, 07/01/09
Iacobellis A et al. - Treatment is only recommended for a well-compensated liver cirrhosis, whereas antiviral therapy is commonly not implemented in cirrhotics with signs of liver decompensation, over the concern that the use of peginterferon and ribavirin might expose patients to severe treatment-related side effects. This review focuses on data available to support both efficacy and safety of antiviral therapy in both compensated and decompensated cirrhotic patients.
Today in Antimicrobials...keeping you current
Receive free subspecialty "5-minute updates" via email
Antiretroviral Therapy With Heart
American Journal of Therapeutics, 11/25/09
Daptomycin Versus Other Antimicrobial Agents for the Treatment of Skin and Soft Tissue Infections: A Meta-Analysis
Annals of Pharmacotherapy, 11/25/09
Lopinavir Cerebrospinal Fluid Steady-State Trough Concentrations in HIV-Infected Adults
Annals of Pharmacotherapy, 11/25/09
Today in Hepatitis...keeping you current
Receive free subspecialty "5-minute updates" via email
Different models of HBeAg seroconversion predicated by on-treatment ALT and HBV DNA profiles
Journal of Viral Hepatitis, 11/25/09
Plasma HCV-RNA decline in the first 48 h identifies hepatitis C virus mono-infected but not HCV/HIV-coinfected patients with an undetectable HCV viral load at week 4 of peginterferon-alfa-2a/ribavirin therapy
Journal of Viral Hepatitis, 11/25/09
Mutation frequency of NS5A in patients vertically infected with HCV genotype 1 predicts sustained virological response to peginterferon alfa-2b and ribavirin combination therapy
Journal of Viral Hepatitis, 11/25/09